AAV vs Lentivirus vs Adenovirus

Introduction

Adeno-associated Virus Vector (AAV), lentivirus, and adenovirus are all widely used viral delivery platforms, but they are not interchangeable. They differ in genome structure, payload capacity, integration tendency, tissue tropism, expression kinetics, immunogenicity, manufacturing considerations, and analytical requirements. This comparison focuses on how researchers can choose a vector system for gene delivery, cell engineering, disease modeling, vaccination research, or preclinical proof-of-concept. When the intended application is still being refined, custom viral vector development should start with the biological question rather than with a preferred viral name.

Figure 1. Approved gene therapy products and delivery platforms.¹

The Core Difference: What Each Vector Is Built to Do

AAV

AAV is a small, non-enveloped single-stranded DNA vector commonly selected for in vivo gene delivery when long-term expression and tissue-directed delivery are important. Its small packaging capacity is a major constraint, but this limitation is partly offset by the availability of multiple serotypes, engineered capsids, compact promoters, and design strategies for smaller payloads. AAV is often explored for gene addition, gene replacement, RNAi delivery, and some genome-editing applications where the required cassette fits within the vector capacity.

Lentiviral Vectors

Lentiviral vectors are enveloped RNA-derived integrating vectors. Their ability to stably deliver genetic material into dividing and non-dividing cells makes them valuable for ex vivo cell engineering, stable cell line generation, CAR-related studies, stem cell work, and durable expression in cultured systems. The integration feature is a strength when stable modification is needed, but it also introduces insertional mutagenesis considerations that must be managed through vector design, safety testing, and careful experimental planning.

Adenoviral Vectors

Adenoviral vectors are non-enveloped double-stranded DNA vectors known for high transduction efficiency, broad cell tropism, strong transient expression, and comparatively large payload capacity. They do not typically integrate into the host genome, which makes them useful when high-level transient expression is acceptable or desired. Their stronger innate immune stimulation can be useful in vaccine and immuno-oncology contexts, but it can be a limitation for studies requiring low inflammatory background.

Table 1. AAV, Lentivirus, and Adenovirus at a Glance

Payload Capacity and Expression Duration

01 Payload size as a practical filter

• AAV: Works best with compact expression cassettes. Oversized genomes reduce packaging efficiency, increase heterogeneity, or favor truncated particles.
• Lentiviral vectors: Allow larger inserts than AAV; often chosen when stable expression is required in dividing cells.
• Adenoviral vectors: Provide larger capacity, especially in helper-dependent formats; can deliver complex cassettes, multiple regulatory elements, or larger transgenes.

02 Expression duration as a second filter

• AAV: Supports long-term episomal expression in many non-dividing tissues. Duration depends on tissue type, promoter, immune context, and vector design.
• Lentiviral vectors: Favored when stable genomic integration is part of the research goal.
• Adenoviral vectors: Provide robust but transient expression. Suitable for immunization, oncolytic or cytotoxic strategies, transient delivery of editing components, or mechanistic studies where long-term expression is unnecessary.

Tropism, Pseudotyping, and Targeting Strategy

Vector tropism determines which tissues or cells are efficiently transduced. AAV tropism is influenced by capsid serotype, engineered capsid features, route of administration, receptor availability, tissue barriers, and immune recognition. Researchers may use AAV capsid or tissue-targeting strategies to improve the match between vector and target biology. Lentiviral tropism is often adjusted by pseudotyping with envelope glycoproteins, which can change entry route, stability, and preferred cell type. Adenoviral tropism can be modified through fiber, hexon, penton, chimeric capsid, peptide incorporation, or antibody-mediated targeting approaches.

Targeting can also occur below the entry step. Tissue-specific promoters, regulatory elements, microRNA response elements, and inducible systems can restrict expression even when vector entry is broader than desired. For this reason, vector selection is not simply a question of capsid or envelope tropism. It is the combined design of entry, genome configuration, promoter, payload, dose, and experimental readout.

Application Scenarios and Vector Fit

01 Application-Guided Vector Selection

• When to choose AAV:
  • in vivo gene replacement with a compact payload
  • Long-term expression desired in liver, muscle, eye, or CNS models
• When to choose lentiviral vectors:
  • ex vivo modification of T cells, hematopoietic cells, or stable reporter lines
  • Durable integration is useful for the experimental goal
• When to choose adenoviral vectors:
  • High-level transient expression
  • Vaccination research, immune stimulation, or oncolysis
  • Delivery of larger cassettes

02 Selection Depends on Project Constraints

The correct answer can change when constraints change:

• Payload too large for AAV → Consider compact redesign, dual-vector approach, lentiviral delivery, adenoviral delivery, or a nonviral method
• Cell type poorly permissive for one vector → Another vector may be more effective
• Minimal innate immune activation required → May avoid adenovirus
• Vaccine project → May deliberately use adenoviral immunogenicity as part of the biological strategy

Table 2. Research Question vs. Recommended Vector Logic

QC and Safety Considerations Are Vector-Specific

Each platform requires a different analytical emphasis. For AAV, quality interpretation often centers on vector genome titer, capsid titer, empty/full ratio, aggregation, genome integrity, potency, and replication-type AAV assessment. For lentivirus, functional titer, p24 or physical particle measurements, vector copy number, envelope pseudotype, residual plasmids, and replication-competent lentivirus testing may be central. For adenovirus, infectious titer, particle-to-infectious unit ratio, replication-competent adenovirus, hexon or particle quantification, cytotoxicity, and innate immune readouts may be especially informative.

Comparisons across vector systems should not rely on a single numerical titer. One vector genome, one transducing unit, and one plaque-forming unit do not describe the same biological property. A meaningful comparison requires dose normalization, matched readouts, relevant target cells, and awareness of vector-specific artifacts. This is why vector potency assessment must be designed around the mechanism of action rather than copied from another vector platform.

How to Choose Among AAV, Lentivirus, and Adenovirus?

A simple decision tree starts with five questions: Is the payload small enough for AAV? Is long-term episomal expression sufficient, or is integration desired? Is the target system in vivo or ex vivo? Is transient high expression acceptable? How much innate immune activation can the experiment tolerate? These questions usually narrow the choice quickly, but final selection still depends on promoter design, target cell accessibility, route, scale, assay readout, and safety requirements.

Researchers should also think about future comparability. A vector that works for a small pilot experiment may not be the easiest to characterize, scale, or compare across lots. For early discovery, speed and transduction efficiency may dominate. For preclinical planning, reproducibility, orthogonal QC, biologically meaningful potency, and safety testing become more important. Choosing the vector early without considering downstream analysis can create avoidable redesign later.

Overview of What Creative Biolabs Can Provide

Creative Biolabs can support comparative vector planning by aligning delivery platform choice with payload size, target cell biology, expression duration, and QC strategy. The most useful support for a comparison page is a cross-platform view that helps teams decide whether AAV, lentiviral, or adenoviral delivery is most appropriate for a specific experimental objective.

For research teams that need to translate vector selection, QC interpretation, or adenoviral vector design into a practical study plan, contact us today to discuss study objectives, sample context, and fit-for-purpose analytical strategy.

Frequently Asked Questions

Reference

1. Wang J H, Gessler D J, Zhan W, et al. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal transduction and targeted therapy, 2024, 9(1): 78. https://doi.org/10.1038/s41392-024-01780-w. Distributed under Open Access license CC BY 4.0, without modification.